chloroquine and derivatives - for infections other than COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 8.18 [0.32, 209.71]> 182%3 studies (3/-)89.5 %highnot evaluable lowimportant-
Influenza-like infection 1.54 [0.62, 3.78]< 10%1 study (1/-)17.5 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

This meta-analysis covered 1 pathologies: 92 92